GAVISCON PEPPERMINT

Posology Adults and children 12 years and over:

One to two tablets after meals and at bedtime.

Children under 12 years:

Should be given only on medical advice.

Duration of treatment:

If symptoms do not improve after seven days, the clinical situation should be reviewed.

Special patient groups:

Elderly: No dose modifications necessary for this age group.

Hepatic impairment:

No modifications necessary. 4).

Adverse reactions have been ranked under headings of frequency using the following convention: Very Rare ≤1/10,000 System Organ Class Frequency Adverse Event Immune System Disorders Very rare Anaphylactic and anaphylactoid reactions.

Hypersensitivity reactions such as urticaria Respiratory, Thoracic and Mediastinal Disorders Very rare Respiratory effects such as bronchospasm Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard

If symptoms do not improve after seven days, the clinical situation should be reviewed. 3 % of the WHO recommended maximum daily intake for sodium. 6 % of the WHO recommended maximum daily intake for sodium. This is based on a two-tablet dose taken four times per day.

This medicinal product is considered high in sodium. This should be particularly taken into account for those on a low salt diet. 6 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

5 mg aspartame in each tablet. Aspartame is hydrolysed in the gastrointestinal tract when orally ingested. One of the major hydrolysis products is phenylalanine. Due to its aspartame content this medicinal product should not be given to patients with phenylketonuria.

Patients with rare hereditary problems of fructose intolerance, glucose- galactose, malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 2.

1.